Feature | ACC | May 18, 2021| Dave Fornell, Editor

ACC 2021 Late Breaking Cardiology Study Results

AMERICAN COLLEGE OF CARDIOLOGY (ACC) Late-breaking clinical trial study presentations at ACC.21. @ACC21 @ACC2021

The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announced for the 2021 American College of Cardiology (ACC) meeting. Top experts will debate and discuss the outcomes of the hottest trials at ACC.21 and explain how it all fits into current cardiology practice. There are five late-breaking clinical trial sessions, three featured clinical research sessions, and two late-breaking clinical trial (LBCT) deep dive sessions to help cardiologists stay up-to-date on the newest clinical research.

Search the sessions at virtual ACC.21 meeting at https://www.abstractsonline.com/pp8/#!/9228/

Joint American College of Cardiology and Journal of the American College of Cardiology Late-Breaking Clinical Trials I
Saturday, May 15, 9 – 10 a.m. ET

   • PARADISE-MI: Sacubitril/valsartan (Entresto) did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril. Prospective ARNI vs. ACE Inhibitor Trial To Determine Superiority In Reducing Heart Failure Events After Myocardial Infarction. Presented by Marc Pfeffer.

   • ADAPTABLE Study: Aspirin 81mg vs. 325mg shows no difference in outcomes. Dosing: A Patient-centric Trial Assessing Benefits And Long-term Effectiveness Trial. Presented by William Schuyler Jones.

   • LAAOS III: The Left Atrial Appendage (LAA) Occlusion Study III — LAA occlusion during cardiac surgery improves outcomes. Presented by Richard Whitlock, M.D.

 

ACC Featured Clinical Research I
Saturday, May 15, 12:15 – 1:30 p.m. ET

   • Results from the EXPLORER-HCM Randomized Clinical Trial: Health Status Benefits of Mavacamten In Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy. 

   • A Report From the NCDR LAAO Registry: One-year Clinical Outcomes Following Watchman Transcatheter Left Atrial Appendage (LAA) Occlusion For Stroke Prevention In Patients With Atrial Fibrillation. 

   • Analysis Of Clinical Outcomes in the NODE-301 Trial: Etripamil Nasal Spray Relieves Symptoms And Reduces Emergency Room Interventions In Patients With Paroxysmal Supraventricular Tachycardia (PSVT). 

   • ATLANTIS: Apixaban is Not Superior to Standard Care in TAVR. 4D Computed Tomography Substudy Shows Valve Thrombosis After Transcatheter Aortic-valve Replacement. 

   • 30-day Results of the Triscend Study: Transfemoral Tricuspid Valve Replacement In Patients With Tricuspid Regurgitation.  

   • Results From the Twilight Study: Sex-Specific Outcomes In High-Risk Patients Receiving Ticagrelor With Or Without Aspirin After Percutaneous Coronary Intervention

 

Joint American College of Cardiology and Journal of the American Medical Association Late-Breaking Clinical Trials II
Sunday, May 16, 8 – 9:30 a.m. ET

   • Effects Of Dapagliflozin Did Not Aid Prevention Of Major Clinical Events And Recovery In Patients With Respiratory Failure Due To COVID-19 - Main Results From The DARE-19 Randomized Trial. Presented by Mikhail Kosiborod.

   • VOYAGER PAD Trial: Reductions In Total Ischemic Events With Rivaroxaban In Patients With Symptomatic Pad After Revascularization. Presented by Rupert Bauersachs.

   • STAMPEDE Trial: Surgical Versus Medical Treatment Of Type 2 Diabetes: 10-year Results of the Stampede Randomized Clinical Trial. Presented by Philip R. Schauer.

   • REHAB-HF Trial: A Novel Physical Rehabilitation Intervention For Older Patients With Acute Decompensated Heart Failure. Presented by Dalane W. Kitzman.

   • Relationship Between Omega-3 Fatty Acid Levels And Major Adverse Cardiovascular Outcomes In Patients With High Cardiovascular Risk. Presented by Steven E. Nissen.

   • PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2x2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol. Presented by Siri Lagethon Heck.

Joint American College of Cardiology and New England Journal of Medicine Late-Breaking Clinical Trials III
Sunday, May 16, 10:45 a.m. – 12:15 p.m. ET

  • The FLOWER-MI Randomized Trial: No Benefit Found for FFR-guided vs. Angio-guided Multivessel Revascularization In ST-Elevation Myocardial Infarction Patients. Presented by Etienne Puymirat. 

   • A Prospective, Multicenter, Randomized, Open-label Trial To Compare Efficacy And Safety Of Clopidogrel Versus Ticagrelor In Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention. Presented by Kiyuk Chang.

   • Host Exam Randomized Controlled Trial: Aspirin vs. Clopidogrel During Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention (PCI). Presented by Hyo-Soo Kim.

   • Late Outcomes Of A 1-hour High Sensitivity Troponin T Protocol In Suspected Acute Coronary Syndromes: A Randomized Clinical Trial. Presented by Derek P. Chew.

   • Randomized Sham-controlled RADIANCE-HTN TRIO Trial: Endovascular Ultrasound Renal Denervation To Treat Hypertension Resistant To A Fixed Dose Triple Medication Pill. Presented by Ajay Kirtane.

ACC Featured Clinical Research II
Sunday, May 16, 2 – 3:30 p.m. ET

   • SAFE-PAD Study: Initial Report From the Safety Assessment Of Femoropopliteal Endovascular Treatment With Paclitaxel-coated Devices Study. Presented by Eric Alexander Secemsky.

   • One-year Follow-up of the REALITY Randomized Clinical Trial: Effect Of A Restrictive vs. Liberal Blood Transfusion Strategy On Major Cardiovascular Events Among Patients With Acute Myocardial Infarction And Anemia. Presented by Jose R. Gonzalez-Juanatey.

   • World Alliance Societies Of Echocardiography COVID Study: Human vs. Machine Learning-based Echocardiography Analysis Finds AI Can Predict Mortality Outcomes in Acute COVID-19 Patients. Presented by Federico M. Asch.

   • Coalition ACTION Trial: Randomized Clinical Trial To Evaluate A Routine Full Anticoagulation Strategy In Patients With Coronavirus Infection (SARS-CoV-2) Admitted To Hospital. Presented by Renato D. Lopes.

   • Inspiration-S Double Blind Randomized Controlled Trial Failed: Atorvastatin Versus Placebo In Critically-ill Patients With COVID-19. Presented by Behnood Bikdeli.

   • ACC 2020 Well Being Study: Impact of COVID-19 on the Global Cardiovascular Workforce. Presented by Laxmi S. Mehta.

 

ACC Late-Breaking Clinical Trials IV
Monday, May 17, 8 – 9:30 a.m. ET

   • Benefits Of Sodium Glucose Co-transporter-1/2 Inhibition With Sotagliflozin Across The Full Spectrum Of Ejection Fraction, Including Heart Failure With Preserved Ejection Fraction. Presented by Deepak L. Bhatt.

   • Primary Results of the CONECT-HF Randomized Clinical Trial: Care Optimization Through Patient And Hospital Engagement Clinical Trial For Heart Failure. Presented by Adam DeVore.

   • Results of the LIFE Trial: Sacubitril/Valsartan (LCZ696) In Patients With Advanced Heart Failure And Reduced Ejection Fraction. Presented by Douglas L. Mann.

   • Pirfenidone In Heart Failure With Preserved Ejection Fraction. Presented by Christopher Miller.

   • Secondary Analysis From GALACTIC-HF: Impact Of Ejection Fraction On The Therapeutic Effect Of Omecamtiv Mecarbil In Patients With Heart Failure And Reduced Ejection Fraction. Presented by John R. Teerlink.

ACC Late-Breaking Clinical Trials V
Monday, May 17, 10:45 a.m. – 12:15 p.m. ET

   • Therapeutic Hypothermia Following Out-Of-Hospital Cardiac Arrest: A Randomized Trial Comparing Mild And Moderate Therapeutic Hypothermia. 

   • Prague OHCA Study: Hyperinvasive Approach Using ECMO In Refractory Out-of-Hospital Cardiac Arrest: An Open-label Randomized Controlled Trial. 

   • RAFT-AF: A Randomized Ablation-based Atrial Fibrillation Rhythm Control Versus Rate Control Trial In Patients With Heart Failure And High Burden Atrial Fibrillation

   • Acute Alcohol Consumption May Have Immediate Effect on Atrial Fibrillation Events. 

   • Finerenone May Delay New Onset Of Atrial Fibrillation Or Flutter In Patients With Chronic Kidney Disease And Type 2 Diabetes. 

ACC Featured Clinical Research III
Monday, May 17, 12:30 – 1:45 p.m. ET

   • One-year Results of the American College Of Cardiology Global Heart Attack Treatment Initiative: Worldwide ST-elevation Myocardial Infarction Care. Presented by Benny J. Levenson.

   • ISCHEMIA Trial: Impact Of Completeness Of Revascularization On Clinical Outcomes In Patients With Stable Ischemic Heart Disease Treated With An Invasive vs. Medical Strategy. Presented by Gregg Stone

   • Insights From the ISCHEMIA Trial: Impact Of Completeness Of Revascularization On Quality-of-life In Patients With Stable Ischemic Heart Disease. Presented by Kreton Mavromatis.

   • Tailor-PCI Randomized Clinical Trial Follow-up Study: Effect Of Genotype-guided Oral P2y12 Inhibitors Vs Conventional Clopidogrel On Long-term Ischemic Outcomes After Percutaneous Coronary Intervention. Presented by Naveen L. Pereira.

   • Effects Of Interleukin-6 Inhibition With Ziltivekimab On Biomarkers Of Inflammation Among Patients At High Risk For Atherosclerotic Events. Presented by Paul M. Ridker.

 

 

Find more news from ACC

ACC Abandons In-person Meeting and Goes Entirely Virtual for 2021 Due to COVID

 

Links to Other Late-breaking Trials: 

ACC 2020 Late-breaking Presentations

ACC 2019 Late-breaking Presentations

ACC 2018 Late-Breaking Trials

TCT 2020 Late-breaking Study Presentations

American Heart Association 2020 Late-breaking Trial Presentations 
 

 

 

Related Content

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no difference if therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI in STEMI with multi-vessel disease.

Feature | ACC | June 08, 2021 | By Dave Fornell, Editor
Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 ...
To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

News | ACC | February 09, 2021 | By Dave Fornell, Editor
UPDATE Feb 22, 2021 — ...
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | April 09, 2020 | Dave Fornell, Editor
Here is the list of American College of Cardiology (ACC) practice-
ACC Cancels 2020 Conference Amid Coronavirus Concerns. #COVID19 #coronavirus #2019nCoV
Feature | ACC | March 09, 2020 | Dave Fornell, Editor
March 9, 2020 — Less than week after the American College of Cardiolog...
American College of Cardiology Names Douglas Drachman Next Annual Scientific Session Vice Chair

Image courtesy of Massachusetts General Hospital

News | ACC | October 08, 2019
Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of Cardiology’s (ACC)...
SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...